



HL7 RCRIM WG

## FHIR AdverseEvent Resource

**CALL MINUTES: Friday, March 10, 2017**

Meet online at [www.webex.com](http://www.webex.com), meeting number: 196 412 889  
 Phone +1 770-657-9270, passcode 7485962

### Attendees: ##

Present	Name	Email	Affiliation
	Behnaz Minaei	Behnaz.Minaei@fda.hhs.gov	FDA
	Brian Peck	bpeck@epic.com	EPIC
	Claude Nanjo	cnanjo@gmail.com	
	Daniela Vanco	Daniela.Vanco@fda.gov	FDA
	David Pettie		Simon Fraser University
	Ed Hammond PhD	william.hammond@duke.edu	Duke
	Edward Helton (NIH/NCI)	helton2@mail.nih.gov	NIH
X	Elaine Ayres (NIH/CC/OD)	EAYres@cc.nih.gov	NIH
	Gary Saner		Reed Technologies
	Iona Thraen	ithraen@utah.gov	VA/Dept of Health Utah
	James Swiger		FDA
X	Jaya Kaja, Ph.D.		IBM Watson Solutions
	Jose Costa Teixeira	jose.a.teixeira@gmail.com	
	Jose Galvez		NIH
	Julie Evans		Samvit Solutions
	Julie James	julie_james@bluewaveinformatics.co.uk	Blue Wave Informatics
	Karen Zimmer	kpzimmer@outlook.com	
	Konstadinos Kidos	konstadinos.kidos@baxalta.com	Baxalta
	M'Lynda Owens	Mlynda.Owens@cognosante.com	Cognosante
	Mary Ann Slack	Maryann.slack@fda.hhs.gov	FDA
	Mead Walker	dmead@comcast.net	Mead Walker Consulting
	Mitra Rocca	mitra.rocca@fda.hhs.gov	FDA
	Pooja Babbrah	Pooja.Babbrah@pocp.com	Point of Care Partners
	Rashad Hasan		FDA
	Raymond Kassekert	raymond.x.kassekert@gsk.com	GSK
X	Rik Smithies	rik@nprogram.co.uk	HL7 UK
	Robert Moura		
	Sheila Connelly		OPTUM
	Smita Hastak		NCI
	Stella Stergiopoulos	stella.stergiopoulos@tufts.edu	Tufts University
	Suranjan De	Suranjan.De@fda.hhs.gov	FDA
	Susan Terrillion (AHRQ/CQuIPS) (CTR)	Susan.Terrillion@AHRQ.hhs.gov	AHRQ
	Ta Jen Chen	Ta Jen Chen@fda.hhs.gov	FDA
	Thomas Felix	thfelix@amgen.com	AMGEN
	Terrie Reed		FDA
	Tony Schueth	Tony.Schueth@pocp.com	Point of Care Partners
	Wayne Kubick	wkubick@hl7.org	CTO HL7
	William Friggle	William.Friggle@sanofi.com	Sanofi
X	William Gregory	William.Gregory@pfizer.com	Pfizer

	Finnie Flores		
X	Joe Quinn		OPTUM
X	Rob Hausam	HL7 Vocab expert	

## Project Wiki

[http://wiki.hl7.org/index.php?title=FHIR\\_Adverse\\_Event\\_Resource](http://wiki.hl7.org/index.php?title=FHIR_Adverse_Event_Resource)

## References

- 1) Search the FDA Acronyms & Abbreviations Database:  
<http://www.fda.gov/AboutFDA/FDAAcronymsAbbreviations/default.htm>
- 2) FHIR Conformance Rules: <http://hl7.org/fhir/conformance-rules.html>
  - a) See 1.12.2 Cardinality

## Agenda

### Agenda for March 10, 2017:

1. Review minutes from February 24
2. Basic constructs – definitions for type, changes to build
  - a. Change type to eventType
  - b. EventType definition and potential terminology bindings
  - c. Make causality a backbone element
  - d. Change seriousness to serious and code with True/False. Amend definition
3. Follow up on Vocab discussion re MedDRA
4. Other issues
  - a. Tracking issues in G-FORGE and Zulip
5. Agenda items for Friday, March 24 at 10 AM ET.

## Minutes

1. Minutes Approval: Move: Bill/Joe
2. Note that GFORGE does not list RCRIM or BRIDG as “owners” of any FHIR resources. Will wait until the new Biomedical Research and Regulation WG is finalized and then ask Lloyd to add. Therefore have not added any to-do items yet to G-FORGE for tracking.
3. Review Decisions
  - a. Agree to use of MedDRA from a standardized terminology approach.
4. Make causality a backbone element
  - a. Causality is a relationship between two things
  - b. Represent event in resource
  - c. Causality – link to other resources
  - d. In regulatory space – there are definitions that are applied
  - e. Are “causality assessment” and “causality method” redundant?
  - f. Need to check E2B and MedWatch – ACTION before changing causality data elements
5. Category codes – just several buckets – use as tags in a resource with searching and querying.
  - a. Use Adverse Event and Potential Adverse Event
  - b. Group was fine with this categorization
  - c. Make category mandatory. Use flag in background to warn that this is a modifier. aCTION

6. Seriousness vs. severity – change to Serious – use True/False. (searchable) In definition of what is serious – can put in definition. If true, it is because of (definition from Bill G.)
  - a. In the regulated space (E2B – R3) – use serious yes/no. Then if serious, then meet which criteria to be classified as serious. E.g. serious – death.
  - b. In MedWatch – narrative text.
  - c. A summary of the definition of a serious adverse event (SAE) from ICH consensus:
    - i. Any untoward medical occurrence that at any dose:
    - ii. Results in death;
    - iii. Is life-threatening;
    - iv. Requires inpatient hospitalization or causes prolongation of existing hospitalization;
    - v. Results in persistent or significant disability/incapacity;
    - vi. Is a congenital anomaly/birth defect; or
    - vii. Requires intervention to prevent permanent impairment or damage (i.e., an important medical event that requires medical judgement).
  - d. If serious – not true or for non-serious
  - e. Add serious.criteria as a placeholder. ACTION
7. Type – need a definition and then determine the terminology to describe. This is how I want to describe what occurred. Maybe type should reference condition and then eliminate reaction. Causality still remains for actual event.
  - a. Retain type but change the actual|potential – include value set with actual and potential types from terminology
  - b. Clinical type
8. Mapping between MedDRA and SNOMED – if needed. Many to one mapping and it is not accurate. 90 % can be mapped from MedDRA to SNOMED. Death is an exact match. But more granular events cannot be mapped. Maintenance is an issue in the map.
9. Rob Hausam will discuss with the HL7 Vocab group any issue that exist regarding the use of MedDRA and example codeable concept bindings.
10. Create condition data element with reference to condition using clinical findings or a subset of clinical findings.
  - a. Resulting condition – point to condition.
  - b. Or call reaction/resulting condition.
  - c. Ability to show short term reaction and long term condition.
  - d. Consider use cases re reaction and resulting condition. ACTION

### 3) ACTION ITEMS

- a) Vocab group re use of MedDRA
- b) Consider how to represent reaction vs. resulting condition
- c) For type – propose value set bindings
- d) For category – make mandatory and add a warning flag
- e) For seriousness – change to serious and determine how to add category or criteria if true
- f) For causality determine what current E2B and MedWatch require – determine if assessment and method are redundant.

### Agenda for March 24, 2017:

1. Review minutes from March 10
2. Review of action items
3. Other issues
  - a. Tracking issues in G-FORGE and Zulip
4. Agenda items for Friday, March 24 at 10 AM ET.